Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
9.53 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 4.695 | 1.064 | 8.752 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 2.06 | 1.897 | 1.846 | 1.834 | 1.391 | 1.151 | 2.682 | 2.576 | 2.169 | 1.132 | 0.809 | 0.582 | 0.467 | 0.274 | 0 | 0 | 0 | 0 |
| Brutowinst
| 2.635 | -0.833 | 6.906 | -1.834 | -1.391 | -1.151 | -2.682 | -2.576 | -2.169 | -1.132 | -0.809 | -0.582 | -0.467 | -0.274 | 0 | 0 | 0 | 0 |
| Brutowinstmarge
| 0.561 | -0.783 | 0.789 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 25.995 | 25.129 | 25.289 | 28.306 | 29.076 | 26.755 | 24.868 | 21.342 | 20.936 | 17.915 | 18.13 | 15.115 | 14.637 | 9.273 | 9.863 | 5.472 | 4.855 | 3.815 |
| Algemene en administratieve kosten
| 9.282 | 8.985 | 7.728 | 8.662 | 8.145 | 7.504 | 7.621 | 7.02 | 6.295 | 6.387 | 5.257 | 4.753 | 3.486 | 2.231 | 2.073 | 0.914 | 0.541 | 0.478 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 9.282 | 8.985 | 7.728 | 8.662 | 8.145 | 7.504 | 7.621 | 7.02 | 6.295 | 6.387 | 5.257 | 4.753 | 3.486 | 2.231 | 2.073 | 0.914 | 0.541 | 0.478 |
| Overige kosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.96 | 0 | 0 | 0 | 0 |
| Bedrijfskosten
| 35.277 | 34.114 | 33.017 | 36.968 | 37.221 | 34.259 | 32.489 | 28.362 | 27.231 | 24.302 | 23.387 | 19.868 | 18.123 | 11.504 | 11.936 | 6.386 | 5.396 | 4.293 |
| Bedrijfsresultaat
| -32.642 | -34.947 | -34.863 | -36.968 | -37.221 | -34.259 | -32.489 | -28.362 | -27.231 | -24.302 | -23.387 | -19.868 | -18.123 | -11.504 | -11.936 | -6.386 | -5.396 | -4.293 |
| Bedrijfsresultaat ratio
| -6.953 | -32.845 | -3.983 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 2.584 | 3.062 | 1.589 | 2.254 | -0.069 | 2.221 | 1.707 | 1.044 | 0.762 | 0.37 | -0.066 | 0.018 | -0.296 | -0.778 | -7.729 | -0.174 | 0.031 | -0.006 |
| Inkomen voor belasting
| -30.058 | -31.885 | -33.274 | -34.714 | -34.988 | -32.038 | -30.782 | -27.318 | -26.469 | -23.932 | -23.44 | -19.837 | -18.405 | -12.276 | -19.656 | -6.558 | -5.364 | -4.302 |
| Inkomen voor belasting ratio
| -6.402 | -29.967 | -3.802 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0.252 | 0.083 | -0.022 | -0.17 | 0.19 | -2.221 | -1.707 | -1.044 | -0.762 | -0.37 | -0.756 | -0.613 | 0.282 | -0.188 | 0.04 | 0.172 | -0.032 | 0.003 |
| Nettowinst
| -30.31 | -31.968 | -33.252 | -34.884 | -35.178 | -29.817 | -29.075 | -26.274 | -25.707 | -23.562 | -23.44 | -19.837 | -18.405 | -12.276 | -19.656 | -6.558 | -5.364 | -4.302 |
| Nettowinstmarge
| -6.456 | -30.045 | -3.799 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.43 | -0.53 | -0.58 | -0.7 | -0.71 | -0.6 | -0.59 | -0.56 | -0.55 | -0.51 | -0.51 | -0.43 | -3.63 | -0.29 | -0.9 | -0.3 | -0.25 | -0.2 |
| Verwaterde WPA
| -0.43 | -0.53 | -0.58 | -0.7 | -0.71 | -0.6 | -0.59 | -0.56 | -0.55 | -0.51 | -0.51 | -0.43 | -3.63 | -0.29 | -0.9 | -0.3 | -0.25 | -0.2 |
| EBITDA
| -30.582 | -33.05 | -33.017 | -36.968 | -35.761 | -34.043 | -32.206 | -27.376 | -26.476 | -23.77 | -23.321 | -19.886 | -17.36 | -11.412 | -11.664 | -6.041 | -5.355 | -4.222 |
| EBITDA ratio
| -6.514 | -31.062 | -3.773 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |